The FDA has greenlit a groundbreaking HIV prevention method—a twice-yearly injection called lenacapavir that’s nearly 100% effective in clinical trials. While this could revolutionize HIV prevention, especially for high-risk groups, there’s a major catch: cost. Will it be accessible to those who need it most?

Editor’s Note: This isn’t just another medical approval—it’s a potential game-changer in the fight against HIV. Imagine replacing daily pills with a shot you only need twice a year. But like many medical breakthroughs, the real hurdle isn’t science; it’s whether the drug will be priced (and covered) in a way that actually reaches people. If it does, this could drastically cut new HIV cases. If not, it’ll join the list of "miracle" treatments that few can afford.